114 related articles for article (PubMed ID: 31119570)
1. Assessment of PARP4 as a candidate breast cancer susceptibility gene.
Prawira A; Munusamy P; Yuan J; Chan CHT; Koh GL; Shuen TWH; Hu J; Yap YS; Tan MH; Ang P; Lee ASG
Breast Cancer Res Treat; 2019 Aug; 177(1):145-153. PubMed ID: 31119570
[TBL] [Abstract][Full Text] [Related]
2. Germline PARP4 mutations in patients with primary thyroid and breast cancers.
Ikeda Y; Kiyotani K; Yew PY; Kato T; Tamura K; Yap KL; Nielsen SM; Mester JL; Eng C; Nakamura Y; Grogan RH
Endocr Relat Cancer; 2016 Mar; 23(3):171-9. PubMed ID: 26699384
[TBL] [Abstract][Full Text] [Related]
3. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer.
Cirello V; Colombo C; Pogliaghi G; Proverbio MC; Rossi S; Mussani E; Tosi D; Bulfamante G; Bonoldi E; Gherardi G; Persani L; Fugazzola L
Mutat Res; 2019 Nov; 816-818():111672. PubMed ID: 31203137
[TBL] [Abstract][Full Text] [Related]
5. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
6. Exome Array Analysis Identifies Variants in SPOCD1 and BTN3A2 That Affect Risk for Gastric Cancer.
Zhu M; Yan C; Ren C; Huang X; Zhu X; Gu H; Wang M; Wang S; Gao Y; Ji Y; Miao X; Yang M; Chen J; Du J; Huang T; Jiang Y; Dai J; Ma H; Zhou J; Wang Z; Hu Z; Ji G; Zhang Z; Shen H; Shi Y; Jin G
Gastroenterology; 2017 Jun; 152(8):2011-2021. PubMed ID: 28246015
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibility.
Lee NY; Hum M; Amali AA; Lim WK; Wong M; Myint MK; Tay RJ; Ong PY; Samol J; Lim CW; Ang P; Tan MH; Lee SC; Lee ASG
Hum Genomics; 2022 Nov; 16(1):61. PubMed ID: 36424660
[TBL] [Abstract][Full Text] [Related]
8. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
9. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
10. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
[TBL] [Abstract][Full Text] [Related]
11. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
12.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
13. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
[TBL] [Abstract][Full Text] [Related]
14. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
Mirabello L; Zhu B; Koster R; Karlins E; Dean M; Yeager M; Gianferante M; Spector LG; Morton LM; Karyadi D; Robison LL; Armstrong GT; Bhatia S; Song L; Pankratz N; Pinheiro M; Gastier-Foster JM; Gorlick R; de Toledo SRC; Petrilli AS; Patino-Garcia A; Lecanda F; Gutierrez-Jimeno M; Serra M; Hattinger C; Picci P; Scotlandi K; Flanagan AM; Tirabosco R; Amary MF; Kurucu N; Ilhan IE; Ballinger ML; Thomas DM; Barkauskas DA; Mejia-Baltodano G; Valverde P; Hicks BD; Zhu B; Wang M; Hutchinson AA; Tucker M; Sampson J; Landi MT; Freedman ND; Gapstur S; Carter B; Hoover RN; Chanock SJ; Savage SA
JAMA Oncol; 2020 May; 6(5):724-734. PubMed ID: 32191290
[TBL] [Abstract][Full Text] [Related]
15. Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Sepahi I; Faust U; Sturm M; Bosse K; Kehrer M; Heinrich T; Grundman-Hauser K; Bauer P; Ossowski S; Susak H; Varon R; Schröck E; Niederacher D; Auber B; Sutter C; Arnold N; Hahnen E; Dworniczak B; Wang-Gorke S; Gehrig A; Weber BHF; Engel C; Lemke JR; Hartkopf A; Nguyen HP; Riess O; Schroeder C
BMC Cancer; 2019 Aug; 19(1):787. PubMed ID: 31395037
[TBL] [Abstract][Full Text] [Related]
16. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG
Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957
[TBL] [Abstract][Full Text] [Related]
19. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Thompson ER; Rowley SM; Li N; McInerny S; Devereux L; Wong-Brown MW; Trainer AH; Mitchell G; Scott RJ; James PA; Campbell IG
J Clin Oncol; 2016 May; 34(13):1455-9. PubMed ID: 26786923
[TBL] [Abstract][Full Text] [Related]
20. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene.
Fostira F; Kostantopoulou I; Apostolou P; Papamentzelopoulou MS; Papadimitriou C; Faliakou E; Christodoulou C; Boukovinas I; Razis E; Tryfonopoulos D; Barbounis V; Vagena A; Vlachos IS; Kalfakakou D; Fountzilas G; Yannoukakos D
J Med Genet; 2020 Jan; 57(1):53-61. PubMed ID: 31300551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
